Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh
Audio Journal of Oncology
COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in which a Wnt-signaling inhibitor—the humanized monoclonal antibody vantictumab—was added to nab-paclitaxel and gemcitabine chemotherapy. Colin Weekes MD PhD, Associate Professor at the University of Colorado in Denver, who reported findings from the trial at the 2016 European Society for Medical Oncology (ESMO) congress, discusses their clinical implications with Peter Goodwin. Debashis Sarker MD FRCP, Senior Lecturer and Consultant in Medical Oncology, at Guy’s, St Thomas’ and King’s College Hospitals, London, who was not involved with the study.
Related Episodes
Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer
CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved ou
ASCO Audio Journal of Oncology – August 1st 2006
John Neoptolemos Wilko Weichert Christophe Nemos Pancreatic Cancer: Adjuvant Chemotherapy Improves Outlook for Patients with Resectable Tumors – ESPAC Trial Results REFERENCE: National Cancer Re
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin